Our innovative pipeline of investigational siRNA therapies is currently focused on diseases with high unmet need in several therapeutic areas. Additionally, we will follow the science and are continually looking at how we can use our technology platform to help new patient populations.
Preclinical
Phase I
Phase II
Phase III
RARE
Divesiran
(TMPRSS6)
Polycythemia Vera (PV)
Other Hematologic Conditions
SLN548
(CFB)
RARE / CARDIOVASCULAR
SLN365
(GPR146)
CARDIOMETABOLIC
Zerlasiran
(LPA)
SLN098
(INHBE)
PARTNERED
SLN312¹
(Undisclosed)
1Licensed to AstraZeneca as part of broader collaboration to discover, develop and commercialize siRNA therapeutics for cardiovascular, renal, metabolic and respiratory diseases